Clinical validation of a next-generation sequencing-based multi-cancer early detection “liquid biopsy” blood test in over 1,000 dogs using an independent testing set: The CANcer Detection in Dogs (CANDiD) study
Fig 4
Case study of a presumably cancer-free 7-year-old, 37 kg female spayed mixed-breed dog that received a Cancer Signal Detected result and was subsequently diagnosed with hemangiosarcoma.
(A) Timeline of NGS-based testing of blood and tissue samples, and the corresponding clinical assessments for the subject. (B) Sequencing data showing no genomic alterations in gDNA derived from white blood cells. (C) Sequencing data showing genomic alterations present in cfDNA from plasma samples obtained at multiple timepoints. (D) Sequencing data showing genomic alterations present in various tissue samples collected during necropsy.